PubRank

Melchiorre Cervello

Author PubWeight™ 53.22‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget 2011 3.43
2 Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 2011 2.72
3 Epidemiology, risk factors, and natural history of hepatocellular carcinoma. Ann N Y Acad Sci 2002 2.10
4 Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 2012 1.96
5 Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget 2012 1.85
6 GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 2014 1.56
7 Antitumor effects of curcumin, alone or in combination with cisplatin or doxorubicin, on human hepatic cancer cells. Analysis of their possible relationship to changes in NF-kB activation levels and in IAP gene expression. Cancer Lett 2005 1.43
8 Akt as a therapeutic target in cancer. Expert Opin Ther Targets 2008 1.41
9 Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 2011 1.40
10 The tumor microenvironment in hepatocellular carcinoma (review). Int J Oncol 2012 1.38
11 Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006 1.31
12 Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs 2008 1.25
13 Emerging MEK inhibitors. Expert Opin Emerg Drugs 2010 1.16
14 Transcriptional regulation of miR-224 upregulated in human HCCs by NFκB inflammatory pathways. J Hepatol 2011 1.08
15 Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. World J Gastroenterol 2006 1.07
16 Advances in targeting signal transduction pathways. Oncotarget 2012 1.06
17 Induction of apoptosis and inhibition of cell growth in human hepatocellular carcinoma cells by COX-2 inhibitors. Ann N Y Acad Sci 2004 0.99
18 Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des 2012 0.96
19 Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. Cell Cycle 2010 0.95
20 Emerging Raf inhibitors. Expert Opin Emerg Drugs 2009 0.94
21 Expression of the IAPs in multidrug resistant tumor cells. Oncol Rep 2004 0.94
22 Potentiation of the antitumor effects of both selective cyclooxygenase-1 and cyclooxygenase-2 inhibitors in human hepatic cancer cells by inhibition of the MEK/ERK pathway. Cancer Biol Ther 2007 0.92
23 Nanostructured lipid carriers-containing anticancer compounds: preparation, characterization, and cytotoxicity studies. Drug Deliv 2007 0.89
24 Cyclooxygenase-2 expression in chronic liver diseases and hepatocellular carcinoma: an immunohistochemical study . Ann N Y Acad Sci 2009 0.89
25 The novel NF-κB inhibitor DHMEQ synergizes with celecoxib to exert antitumor effects on human liver cancer cells by a ROS-dependent mechanism. Cancer Lett 2012 0.89
26 IL-6 -174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 2011 0.89
27 Antitumor effects of the novel NF-kappaB inhibitor dehydroxymethyl-epoxyquinomicin on human hepatic cancer cells: analysis of synergy with cisplatin and of possible correlation with inhibition of pro-survival genes and IL-6 production. Int J Oncol 2006 0.89
28 Prostaglandin E2 receptors and COX enzymes in human hepatocellular carcinoma: role in the regulation of cell growth. Ann N Y Acad Sci 2009 0.88
29 Association between single nucleotide polymorphisms in the cyclooxygenase-2, tumor necrosis factor-α, and vascular endothelial growth factor-A genes, and susceptibility to hepatocellular carcinoma. OMICS 2011 0.88
30 Resistance to diverse apoptotic triggers in multidrug resistant HL60 cells and its possible relationship to the expression of P-glycoprotein, Fas and of the novel anti-apoptosis factors IAP (inhibitory of apoptosis proteins). Cancer Lett 2002 0.86
31 Antitumor effects of dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, in human liver cancer cells are mediated through a reactive oxygen species-dependent mechanism. Mol Pharmacol 2009 0.86
32 Significance of autologous interleukin-6 production in the HA22T/VGH cell model of hepatocellular carcinoma. Ann N Y Acad Sci 2006 0.85
33 Histamine and spontaneously released mast cell granules affect the cell growth of human hepatocellular carcinoma cells. Exp Mol Med 2007 0.84
34 Novel cationic solid-lipid nanoparticles as non-viral vectors for gene delivery. J Drug Target 2007 0.83
35 Aromatase and amphiregulin are correspondingly expressed in human liver cancer cells. Ann N Y Acad Sci 2009 0.83
36 Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine. Cell Cycle 2012 0.83
37 Cloning and expression of a type IX-like collagen in tissues of the ascidian Ciona intestinalis. Biochim Biophys Acta 2002 0.82
38 Frequent alteration of the Yin Yang 1/Raf-1 kinase inhibitory protein ratio in hepatocellular carcinoma. OMICS 2011 0.82
39 The selective cyclooxygenase-1 inhibitor SC-560 suppresses cell proliferation and induces apoptosis in human hepatocellular carcinoma cells. Int J Mol Med 2006 0.80
40 GSK-3beta is a critical mediator of tetrandrine induced cell cycle arrest and cytotoxicity. Cancer Biol Ther 2008 0.80
41 Effects of ectopic expression of NGAL on doxorubicin sensitivity. Oncotarget 2012 0.79
42 Response to antiviral therapy and hepatic expression of cyclooxygenases in chronic hepatitis C. Eur J Gastroenterol Hepatol 2007 0.77
43 Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interferon treatment. Intervirology 2003 0.77
44 Expression of IAPs and alternative splice variants in hepatocellular carcinoma tissues and cells. Ann N Y Acad Sci 2004 0.76
45 Synthesis and characterization of polyaminoacidic polycations for gene delivery. Biomaterials 2005 0.76
46 Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J Nanobiotechnology 2014 0.75
47 Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. Curr Pharm Des 2016 0.75
48 Induction of apoptosis by the adenosine derivative IB-MECA in parental or multidrug-resistant HL-60 leukemia cells: possible relationship to the effects on inhibitor of apoptosis protein levels. Chemotherapy 2005 0.75
49 NAIP-deltaEx10-11: a novel splice variant of the apoptosis inhibitor NAIP differently expressed in drug-sensitive and multidrug-resistant HL60 leukemia cells. Leuk Res 2002 0.75